This finding deserves further investigation in studies directly comparing XO inhibitors with plasma UA-lowering agents, such as a urate transporter 1 (URAT1) inhibitor, on NASH development. Here, SLC22A12 is linked to metabolic dysfunction-associated steatohepatitis.